Your browser is no longer supported. Please, upgrade your browser.
Settings
NVCR NovoCure Limited daily Stock Chart
NVCR [NASD]
NovoCure Limited
Index- P/E- EPS (ttm)-0.69 Insider Own1.90% Shs Outstand97.58M Perf Week-5.52%
Market Cap4.21B Forward P/E97.38 EPS next Y0.44 Insider Trans-47.84% Shs Float76.49M Perf Month-13.72%
Income-63.60M PEG- EPS next Q-0.14 Inst Own68.60% Short Float5.27% Perf Quarter-7.13%
Sales248.10M P/S16.97 EPS this Y36.50% Inst Trans3.55% Short Ratio5.90 Perf Half Y-5.02%
Book/sh1.21 P/B35.65 EPS next Y263.00% ROA-20.00% Target Price56.00 Perf Year72.56%
Cash/sh2.52 P/C17.12 EPS next 5Y- ROE-57.10% 52W Range23.61 - 56.67 Perf YTD28.85%
Dividend- P/FCF- EPS past 5Y5.90% ROI-19.60% 52W High-23.88% Beta3.13
Dividend %- Quick Ratio4.60 Sales past 5Y88.70% Gross Margin67.70% 52W Low82.72% ATR1.73
Employees598 Current Ratio5.00 Sales Q/Q29.80% Oper. Margin-13.60% RSI (14)31.43 Volatility4.40% 4.08%
OptionableYes Debt/Eq1.33 EPS Q/Q67.20% Profit Margin-25.60% Rel Volume0.45 Prev Close42.22
ShortableYes LT Debt/Eq1.33 EarningsMay 02 BMO Payout- Avg Volume682.64K Price43.14
Recom2.20 SMA20-6.73% SMA50-12.79% SMA2003.25% Volume306,355 Change2.18%
Mar-20-19Initiated SunTrust Hold
Nov-02-18Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18Initiated Evercore ISI Outperform $46
Apr-18-18Reiterated Mizuho Buy $28 → $32
Feb-23-18Reiterated Mizuho Buy $25 → $28
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Dec-02-15Initiated Deutsche Bank Hold $28
Oct-27-15Initiated Wedbush Outperform
Oct-27-15Initiated JP Morgan Overweight
Oct-27-15Initiated JMP Securities Mkt Outperform $43
Apr-15-19 07:30AM  Novocure Publishes 2018 Annual Report Featuring Companys Vision, Mission and Values Business Wire
Apr-10-19 02:10PM  What You Should Know About NovoCure Limited's (NASDAQ:NVCR) Financial Strength Simply Wall St.
Apr-06-19 03:45PM  Why Novocure Stock Fell More Than 10% in March Motley Fool
Apr-03-19 07:30AM  Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019 Business Wire
Apr-02-19 07:30AM  Novocure to Report First Quarter 2019 Financial Results Business Wire
Mar-29-19 07:50AM  Investor Expectations to Drive Momentum within Apple Hospitality REIT, Superior Energy Services, US Foods Holding, NovoCure, FTS International, and Envestnet Discovering Underlying Factors of Influence GlobeNewswire
Mar-22-19 07:30AM  Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer Business Wire -5.92%
Mar-21-19 07:30AM  Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019 Business Wire
06:52AM  Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role MarketWatch
06:30AM  Novocures Chief Science Officer Retires after 17 Years of Service Business Wire
Mar-18-19 07:30AM  Novocure to Participate in Oppenheimers 29th Annual Healthcare Conference Business Wire
Mar-12-19 09:37AM  Does NovoCure Limiteds (NASDAQ:NVCR) Past Performance Indicate A Weaker Future? Simply Wall St.
Mar-08-19 08:45AM  Options Traders Expect Huge Moves in NovoCure (NVCR) Stock Zacks
Mar-04-19 11:58PM  Edited Transcript of NVCR earnings conference call or presentation 28-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -5.83%
06:15PM  Novocure Ltd (NVCR) CEO Asaf Danziger Sold $5.6 million of Shares GuruFocus.com
Feb-28-19 03:21PM  NovoCure (NVCR) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:00AM  Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Business Wire
Feb-21-19 11:49AM  3 Medical Device Companies for Your Watchlist Motley Fool
Jan-23-19 11:38AM  How Many Insiders Sold NovoCure Limited (NASDAQ:NVCR) Shares? Simply Wall St.
Jan-18-19 06:15PM  Novocure Ltd (NVCR) CEO Asaf Danziger Sold $9 million of Shares GuruFocus.com
Jan-16-19 06:15PM  Novocure Ltd (NVCR) CEO Asaf Danziger Sold $8.7 million of Shares GuruFocus.com
Jan-11-19 12:24PM  Tamarack Capital Managements Return, AUM, and Holdings Insider Monkey
Jan-07-19 04:05PM  Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update Business Wire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-24-18 09:44AM  Is NovoCure a Buy? Motley Fool
Dec-21-18 07:30AM  Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-17-18 02:20PM  What Kind Of Shareholder Owns Most NovoCure Limited (NASDAQ:NVCR) Stock? Simply Wall St.
07:30AM  Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields Business Wire
Dec-16-18 09:10AM  Is NovoCure Limited (NVCR) A Good Stock To Buy? Insider Monkey
Dec-12-18 11:49AM  3 Top Medical Device Stocks to Buy Now Motley Fool
Dec-07-18 07:55AM  Recent Analysis Shows Moody's, Hershey, NovoCure, Mohawk Industries, La-Z-Boy, and Lockheed Martin Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Dec-06-18 07:30AM  Sub-Group Analysis of Novocures EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival Business Wire
Nov-14-18 07:30AM  Zai Lab and Novocure Awarded Deal of the Year GlobeNewswire
07:30AM  Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China Business Wire
Nov-13-18 08:01PM  3 Top Healthcare Stocks to Buy in November Motley Fool
08:24AM  Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-07-18 04:00PM  Novocure and Zai Lab to Host Investor Event Business Wire +8.33%
12:25PM  NovoCure Limited (NASDAQ:NVCR): Is Breakeven Near? Simply Wall St.
11:22AM  Here's Why NovoCure Fell 36.8% in October Motley Fool
Oct-30-18 02:04PM  Edited Transcript of NVCR earnings conference call or presentation 25-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
07:30AM  New Research Coverage Highlights HomeStreet, Cousins Properties, Carbo Ceramics, Cowen Group, CTS, and NovoCure Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-25-18 03:11PM  Here's Why Novocure Is Tumbling Today Motley Fool -18.98%
09:05AM  NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:00AM  Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update Business Wire
Oct-24-18 04:00PM  Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors Business Wire
Oct-23-18 05:57PM  Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma Business Wire
Oct-22-18 07:30AM  Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields Business Wire
Oct-18-18 10:33AM  NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For Zacks
07:30AM  Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune® Business Wire
Oct-11-18 08:03AM  Why Novocure Stock Jumped 16.3% in September Motley Fool
Oct-04-18 09:08AM  Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018 Business Wire
Oct-02-18 11:51AM  3 Medical Devices Stocks to Buy InvestorPlace
Oct-01-18 08:36AM  Novocure to Report Third Quarter 2018 Financial Results Business Wire
Sep-25-18 07:30AM  Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer Business Wire
Sep-14-18 03:04PM  What Investors Should Know About NovoCure Limiteds (NASDAQ:NVCR) Financial Strength Simply Wall St.
Sep-13-18 10:57AM  5 Medical Device Stocks With Impressive Staying Power InvestorPlace
Sep-12-18 07:30AM  Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Business Wire
Sep-10-18 10:31AM  Why Novocure Gained 33% in August Motley Fool
Sep-06-18 11:24AM  Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles Investing.com +5.34%
08:00AM  Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and NovoCure ACCESSWIRE
Sep-05-18 05:00PM  Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control Business Wire
Aug-31-18 04:38PM  This brain cancer drug stock has been on a tear Yahoo Finance
Aug-26-18 07:15PM  3 Small-Cap Healthcare Stocks for Your Watch List Motley Fool
Aug-24-18 08:00AM  Today's Research Reports on Trending Tickers: Exact Sciences and NovoCure ACCESSWIRE
Aug-23-18 07:55AM  Research Report Identifies Genesis Healthcare, Maiden, Ichor, Armstrong World Industries, Rexnord, and NovoCure with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-17-18 07:30AM  This $7 Biotech Stock Could Be Worth $20 or More After Recent Developments ACCESSWIRE
Aug-15-18 08:38AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:30AM  Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer Business Wire
Aug-06-18 12:18PM  Forget Bitcoin: You're Better Off Buying These 3 Stocks Motley Fool
Aug-03-18 07:30AM  Novocure to Present at Two Upcoming Investor Conferences Business Wire
Aug-02-18 07:30AM  Novocure Announces Addition to Its Board of Directors Business Wire
Jul-31-18 07:30AM  Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer Business Wire
Jul-26-18 07:19PM  Edited Transcript of NVCR earnings conference call or presentation 26-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
06:00AM  Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update Business Wire
Jul-19-18 07:30AM  Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting Business Wire
Jul-17-18 08:54AM  NovoCure (NVCR) Catches Eye: Stock Jumps 7.4% Zacks
07:30AM  Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society Business Wire
Jul-16-18 07:05AM  Free Pre-Market Technical Recap on Nevro and Three Additional Medical Equipment Stocks ACCESSWIRE +7.40%
Jul-14-18 03:35PM  Here's Why Novocure Ltd. Rose 55% in the First Half of 2018 Motley Fool
Jul-06-18 09:13AM  Trade of the Day: Novocure Ltd (NVCR) InvestorPlace
Jul-02-18 08:00AM  Novocure Appoints Pritesh Shah as Chief Commercial Officer Business Wire
07:30AM  Novocure to Report Second Quarter 2018 Financial Results Business Wire
Jun-21-18 02:40PM  NovoCure's Charts Look Bullish TheStreet.com
Jun-20-18 07:01PM  Cramer's lightning round: The pecking order for my favori... CNBC Videos
06:49PM  Cramer's lightning round: The pecking order for my favorite cybersecurity stocks CNBC
Jun-15-18 08:10AM  Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jun-04-18 10:37AM  The Probable Reason Behind NovoCure's Double-Digit Drop Today Motley Fool -7.51%
07:30AM  Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018 Business Wire
May-31-18 04:05PM  Novocure Announces Changes to Its Board of Directors Business Wire
07:20AM  Breakfast Technical Briefing on NovoCure and Three Other Additional Medical Equipment Stocks ACCESSWIRE
May-14-18 12:02PM  Best Growth Stock in May Simply Wall St.
May-11-18 11:46AM  Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT Thomson Reuters StreetEvents
Apr-26-18 04:53PM  This Explains Why NovoCure Is Surging Today Motley Fool +9.73%
11:55AM  NovoCure: 1Q Earnings Snapshot Associated Press
06:00AM  Novocure Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
06:00AM  Novocure Ltd. to Host Earnings Call ACCESSWIRE
Apr-25-18 11:10AM  NovoCure (NVCR) Shares March Higher, Can It Continue Zacks
Apr-19-18 08:00AM  Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.04%
07:10AM  Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma ACCESSWIRE
Apr-18-18 08:31AM  NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session Zacks
Markets a wearable electric field device for treating glioblastoma brain cancer.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEUNG GABRIELDirectorApr 10Option Exercise3.445,00017,20065,000Apr 12 04:05 PM
LEUNG GABRIELDirectorApr 10Sale45.955,000229,75060,000Apr 12 04:05 PM
Ambrogi Michael J.Chief Operating OfficerApr 02Option Exercise14.3715,516222,965201,190Apr 03 04:25 PM
Ambrogi Michael J.Chief Operating OfficerApr 02Sale47.2415,516733,039185,674Apr 03 04:25 PM
Ambrogi Michael J.Chief Operating OfficerApr 01Option Exercise13.3134,375457,594207,549Apr 03 04:25 PM
Ambrogi Michael J.Chief Operating OfficerApr 01Sale47.3934,3751,629,014185,674Apr 03 04:25 PM
Shah PriteshChief Commercial OfficerMar 28Option Exercise6.8032,521221,29176,212Apr 01 04:15 PM
LEUNG GABRIELDirectorMar 11Option Exercise3.445,00017,20065,000Mar 12 04:56 PM
LEUNG GABRIELDirectorMar 11Sale48.315,000241,55060,000Mar 12 04:56 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMar 05Option Exercise3.4431,234107,44597,498Mar 06 04:18 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMar 05Sale53.4031,2341,668,02166,264Mar 06 04:18 PM
Danziger AsafChief Executive OfficerMar 04Option Exercise14.3716,268233,771250,025Mar 06 04:17 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMar 04Option Exercise3.4458,766202,155106,264Mar 06 04:18 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMar 04Sale54.2258,7663,186,29166,264Mar 06 04:18 PM
Danziger AsafChief Executive OfficerMar 04Sale55.8916,268909,286233,757Mar 06 04:17 PM
Shah PriteshChief Commercial OfficerMar 01Option Exercise13.7740,586558,81042,136Mar 04 04:13 PM
Danziger AsafChief Executive OfficerMar 01Option Exercise14.37100,0001,437,000333,757Mar 04 04:15 PM
LEUNG GABRIELDirectorMar 01Option Exercise3.4425,00086,00085,000Mar 04 04:14 PM
Shah PriteshChief Commercial OfficerMar 01Sale55.6340,5862,257,69725,239Mar 04 04:13 PM
Danziger AsafChief Executive OfficerMar 01Sale55.57100,0005,556,582233,757Mar 04 04:15 PM
LEUNG GABRIELDirectorMar 01Sale55.0125,0001,375,27560,000Mar 04 04:14 PM
Danziger AsafChief Executive OfficerFeb 28Option Exercise14.3790312,976234,660Mar 01 04:31 PM
Longsworth Todd ChristopherGeneral CounselFeb 28Sale53.682,368127,11436,835Mar 01 04:30 PM
Shah PriteshChief Commercial OfficerFeb 28Sale53.681,55883,63325,239Mar 01 04:32 PM
Danziger AsafChief Executive OfficerFeb 28Sale54.4090349,119233,757Mar 01 04:31 PM
DOYLE WILLIAM FExecutive ChairmanFeb 28Sale53.683,097166,247918,306Mar 01 04:52 PM
Ambrogi Michael J.Chief Operating OfficerFeb 28Sale53.682,397128,671169,305Mar 01 04:35 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 28Sale53.683,288176,50066,264Mar 01 04:36 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 27Option Exercise52.907,717408,22969,552Mar 01 04:36 PM
Ambrogi Michael J.Chief Operating OfficerFeb 27Option Exercise52.906,174326,605171,702Mar 01 04:35 PM
Kirson Eilon D.Chief Science OfficerFeb 27Option Exercise52.906,945367,391152,408Mar 01 04:34 PM
DOYLE WILLIAM FExecutive ChairmanFeb 27Option Exercise52.909,260489,854921,403Mar 01 04:52 PM
Danziger AsafChief Executive OfficerFeb 27Option Exercise52.909,260489,854233,757Mar 01 04:31 PM
Shah PriteshChief Commercial OfficerFeb 27Option Exercise52.903,087163,30226,797Mar 01 04:32 PM
Longsworth Todd ChristopherGeneral CounselFeb 27Option Exercise52.905,556293,91239,203Mar 01 04:30 PM
Shah PriteshChief Commercial OfficerFeb 25Sale53.636,377341,98623,710Feb 26 05:56 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 25Sale53.6318,6471,000,00161,835Feb 26 05:58 PM
Ambrogi Michael J.Chief Operating OfficerFeb 25Sale53.6312,230655,870165,528Feb 26 06:00 PM
Longsworth Todd ChristopherGeneral CounselFeb 25Sale53.639,325500,08133,647Feb 26 05:54 PM
Longsworth Todd ChristopherGeneral CounselFeb 22Option Exercise53.3821,6671,156,58442,972Feb 26 05:54 PM
Danziger AsafChief Executive OfficerFeb 22Option Exercise53.3853,3332,846,916224,497Feb 26 05:51 PM
Ambrogi Michael J.Chief Operating OfficerFeb 22Option Exercise53.3831,2001,665,456177,758Feb 26 06:00 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 22Option Exercise53.3843,3332,313,11680,482Feb 26 05:58 PM
Kirson Eilon D.Chief Science OfficerFeb 22Option Exercise53.3836,4001,943,032145,463Feb 26 05:57 PM
Shah PriteshChief Commercial OfficerFeb 22Option Exercise53.3813,000693,94030,087Feb 26 05:56 PM
LEUNG GABRIELDirectorFeb 11Option Exercise3.445,00017,20065,000Feb 13 04:08 PM
LEUNG GABRIELDirectorFeb 11Sale49.595,000247,95060,000Feb 13 04:08 PM
Ambrogi Michael J.Chief Operating OfficerFeb 04Option Exercise7.1521,000150,150167,558Feb 05 04:16 PM
Ambrogi Michael J.Chief Operating OfficerFeb 04Sale49.5321,0001,040,193146,558Feb 05 04:16 PM
Ambrogi Michael J.Chief Operating OfficerFeb 01Option Exercise7.1537,500268,125184,058Feb 05 04:16 PM
Ambrogi Michael J.Chief Operating OfficerFeb 01Sale49.0337,5001,838,654146,558Feb 05 04:16 PM
Longsworth Todd ChristopherGeneral CounselJan 25Option Exercise7.1511,87484,89933,179Jan 28 04:15 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 25Option Exercise3.4435,000120,40072,149Jan 28 04:12 PM
LEUNG GABRIELDirectorJan 25Option Exercise3.4420,00068,80080,000Jan 28 04:13 PM
Longsworth Todd ChristopherGeneral CounselJan 25Sale50.1511,874595,48121,305Jan 28 04:15 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 25Sale49.2035,0001,722,00037,149Jan 28 04:12 PM
LEUNG GABRIELDirectorJan 25Sale50.0020,0001,000,00060,000Jan 28 04:13 PM
Longsworth Todd ChristopherGeneral CounselJan 24Option Exercise7.1515,000107,25036,305Jan 28 04:15 PM
Longsworth Todd ChristopherGeneral CounselJan 24Sale48.1515,000722,25021,305Jan 28 04:15 PM
Danziger AsafChief Executive OfficerJan 23Option Exercise7.4888,695663,439259,859Jan 25 04:10 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 23Option Exercise3.4435,000120,40072,149Jan 25 04:12 PM
Danziger AsafChief Executive OfficerJan 23Sale47.4888,6954,211,239171,164Jan 25 04:10 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 23Sale47.3535,0001,657,25037,149Jan 25 04:12 PM
Danziger AsafChief Executive OfficerJan 18Option Exercise3.4446,863161,209218,027Jan 22 05:13 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 18Option Exercise3.4430,000103,20067,149Jan 22 05:14 PM
Danziger AsafChief Executive OfficerJan 18Sale45.9146,8632,151,356171,164Jan 22 05:13 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 18Sale45.9030,0001,376,91037,149Jan 22 05:14 PM
Kirson Eilon D.Chief Science OfficerJan 17Option Exercise14.3768,813988,843177,876Jan 18 04:13 PM
Danziger AsafChief Executive OfficerJan 17Option Exercise3.44100,000344,000271,164Jan 18 04:15 PM
Kirson Eilon D.Chief Science OfficerJan 17Sale45.2568,8133,113,788109,063Jan 18 04:13 PM
Danziger AsafChief Executive OfficerJan 17Sale45.26100,0004,526,400171,164Jan 18 04:15 PM
Longsworth Todd ChristopherGeneral CounselJan 16Option Exercise7.1515,000107,25036,305Jan 18 04:12 PM
Kirson Eilon D.Chief Science OfficerJan 16Option Exercise14.37100,0001,437,000209,063Jan 18 04:13 PM
Danziger AsafChief Executive OfficerJan 16Option Exercise3.44100,000344,000271,164Jan 18 04:15 PM
Shah PriteshChief Commercial OfficerJan 16Option Exercise15.5525,000388,75029,587Jan 18 04:17 PM
LEUNG GABRIELDirectorJan 16Option Exercise3.4420,00068,80080,000Jan 18 04:19 PM
Longsworth Todd ChristopherGeneral CounselJan 16Sale45.1515,000677,25021,305Jan 18 04:12 PM
Kirson Eilon D.Chief Science OfficerJan 16Sale45.11100,0004,511,000109,063Jan 18 04:13 PM
Danziger AsafChief Executive OfficerJan 16Sale45.05100,0004,505,304171,164Jan 18 04:15 PM
Shah PriteshChief Commercial OfficerJan 16Sale45.0025,0001,125,07517,087Jan 18 04:17 PM
LEUNG GABRIELDirectorJan 16Sale45.0020,000900,06060,000Jan 18 04:19 PM
Danziger AsafChief Executive OfficerJan 15Option Exercise3.44100,000344,000271,164Jan 16 04:31 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 15Option Exercise3.4430,000103,20067,149Jan 16 04:32 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 15Sale44.2030,0001,326,00037,149Jan 16 04:32 PM
Danziger AsafChief Executive OfficerJan 15Sale43.49100,0004,348,800171,164Jan 16 04:31 PM
Danziger AsafChief Executive OfficerJan 14Option Exercise3.44100,000344,000271,164Jan 16 04:31 PM
Danziger AsafChief Executive OfficerJan 14Sale43.52100,0004,352,400171,164Jan 16 04:31 PM
Shah PriteshChief Commercial OfficerJan 11Option Exercise12.4326,251326,30234,587Jan 14 04:35 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 11Option Exercise3.4430,000103,20067,149Jan 14 04:30 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerJan 11Sale42.3530,0001,270,50037,149Jan 14 04:30 PM
Shah PriteshChief Commercial OfficerJan 11Sale42.0026,2511,102,64717,087Jan 14 04:35 PM
LEUNG GABRIELDirectorJan 10Option Exercise3.445,00017,20065,000Jan 14 04:32 PM
Ambrogi Michael J.Chief Operating OfficerJan 10Option Exercise14.3754,930789,344201,488Jan 14 04:34 PM
LEUNG GABRIELDirectorJan 10Sale39.915,000199,55060,000Jan 14 04:32 PM
Ambrogi Michael J.Chief Operating OfficerJan 10Sale40.8854,9302,245,810146,558Jan 14 04:34 PM
LEUNG GABRIELDirectorJan 09Option Exercise3.4420,00068,80080,000Jan 11 04:23 PM
Shah PriteshChief Commercial OfficerJan 09Option Exercise14.378,988129,15826,075Jan 11 04:16 PM
Ambrogi Michael J.Chief Operating OfficerJan 09Option Exercise13.64100,0001,364,250221,558Jan 11 04:18 PM
Longsworth Todd ChristopherGeneral CounselJan 09Option Exercise7.1515,000107,25036,305Jan 11 04:21 PM
Ambrogi Michael J.Chief Operating OfficerJan 09Sale40.00100,0004,000,000146,558Jan 11 04:18 PM